Trials / Recruiting
RecruitingNCT07230691
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Prospective, Multi Country, Observational Study of Clinical Outcomes in EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Approved Amivantamab-containing Regimens Under Standard Clinical Practice
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 380 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the clinical and health-related outcomes of amivantamab-containing regimens for the treatment of common epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC; most common type of lung cancer) in a real-world setting. Metastatic NSCLC is when this disease spreads to other parts of body. NSCLC may occur due to mutations (changes) in many genes including epidermal growth factor receptor (EGFR).
Conditions
Timeline
- Start date
- 2025-12-03
- Primary completion
- 2030-11-19
- Completion
- 2030-12-17
- First posted
- 2025-11-17
- Last updated
- 2026-04-13
Locations
48 sites across 7 countries: Austria, Czechia, Germany, Israel, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT07230691. Inclusion in this directory is not an endorsement.